Business Wire

CA-ALORICA

Share
Alorica Introduces ReVoLT – Breakthrough Technology Enabling Real-Time Voice Translation for 75 Languages and 200 Dialects, a Game Changer in Multilingual CX Delivery

Alorica Inc., a global customer experience (CX) leader, announced today the launch of its Real-time Voice Language Translation (ReVoLT), effectively eliminating language barriers during live customer interactions. This offering is the centrepiece of Alorica Clear, an AI-powered solution suite that revolutionises how businesses communicate with their global customer base through seamless voice language translation, accent localisation and background noise cancellation. The services are enabled by an exclusive linguistic processing platform that applies AI to offer translation capabilities designed for multilingual CX across digital and voice channels.

As companies personalise and localise their customer experiences, they face language barriers and cultural nuances that complicate operations and challenge ROI. ReVoLT removes these pain points by providing real-time, bi-directional voice translation in 75 languages. By integrating this technology, organisations can set up their service operations anywhere and support customers across the globe in their native language, improving service and reducing costs by up to 50%.

“The demand for multilingual service is exploding due to an increasingly interconnected world where brands engage consumers through personalised experiences,” stated Mike Clifton, Alorica’s Chief Growth & Transformation Officer. “Customers place high value on localisation, but CX leaders are struggling to efficiently scale their contact centres across multiple geographies. Multilingual support has historically required fragmented queues or locations, which adds complexity and cost while reducing quality. ReVoLT is our strategic response to this growing need, empowering our clients to deliver centralised, effective, and culturally sensitive customer support while achieving significant savings and improved service.”

According to industry data, 29% of businesses cite losing customers because they did not offer multilingual support, and 70% of end users say they feel more loyal to companies that provide services in their native language. Alorica Clear enriches customer interactions and enhances business outcomes through the transformative power of AI, machine translation and large language models.

The Alorica Clear solution suite eliminates friction in global CX delivery through:

  • Real-Time Voice Translation – ReVoLT provides bi-directional voice translation, grammar correction and transcription for 75 languages and 200 dialects with high scalability and security.
  • Digital Translation – Supporting over 100 languages and dialects, agents can seamlessly deliver multilingual digital transactions via chat, email, and documents.
  • Multilingual Cognitive Assistant – Interprets and resolves inquiries digitally in over 100 languages and is uniquely trained to brand voice and objectives.
  • Accent Localisation – Mitigates agents' accents during live interactions, adapting to the natural language of the customer to ensure comprehension.
  • Noise Cancellation – Eliminates background noise and distractions, tailored to Alorica Anywhere, the company’s work-at-home solution.

“We believe language personalisation is one of the most compelling applications of this exclusive technology, removing longstanding barriers to providing localised service with high quality and efficiency. Real-time voice language translation embodies our commitment to seamless and effective customer experiences, regardless of language differences,” shared Clifton.

Alorica Clear joins the portfolio of technology-infused offerings by Alorica IQ – the company’s digital and innovation practice focused on user experience design, technology solutions and analytics. Experience Alorica Clear’s exclusive Real-Time Voice Language Translation capabilities here.

About Alorica

Alorica creates insanely great digital customer experiences at scale. Our team of 100,000 solutionists, technologists and operators partner with global brands and disruptive innovators to deliver digitally charged, tailored interactions customers crave. With a track record of creating long-term loyalty, Alorica brings actionable insights, proven processes and CX leadership that deliver outcomes critical to clients’ objectives, whether they’re focused on digital optimisation, customer engagement or market expansion. Our digital practice— Alorica IQ—designs, integrates and optimises best-of-breed technology solutions across the customer experience to improve service and increase operational efficiency. Alorica drives CX innovation for the best clients around the globe from its award-winning operations in 19 countries worldwide. To learn more, visit www.alorica.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240304683403/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release

Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu

HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release

Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release

- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o

SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release

Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye